Literature DB >> 28910456

Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma.

Yin P Hung1, Fei Dong1, Jaclyn C Watkins1, Valentina Nardi2, Raphael Bueno3, Paola Dal Cin1, John J Godleski1, Christopher P Crum1, Lucian R Chirieac1.   

Abstract

IMPORTANCE: Malignant peritoneal mesothelioma is a rare, aggressive tumor arising from the peritoneal lining, induced by asbestos, therapeutic radiation, or germline mutations. Nevertheless, the molecular features remain largely unknown.
OBJECTIVE: To investigate anaplastic lymphoma kinase (ALK) rearrangements in a large series of peritoneal mesothelioma and characterize the mutational landscape of these tumors. DESIGN, SETTING, AND PARTICIPANTS: We studied 88 consecutive patients (39 men, 49 women; median age 61, range 17-84 years) with peritoneal mesotheliomas diagnosed at a single institution between 2005 and 2015. We identified ALK-positive mesotheliomas by immunohistochemistry and confirmed ALK rearrangement by fluorescence in situ hybridization (FISH). In ALK-rearranged cases, we characterized the fusion partners using targeted next-generation sequencing of both tumor DNA and RNA. In select cases, we quantified asbestos fibers by combined scanning electron microscopy and x-ray spectroscopy. We also explored ALK rearrangement in a separate series of 205 patients with pleural mesothelioma. MAIN OUTCOMES AND MEASURES: Identification and characterization of novel ALK rearrangements and correlations with clinicopathologic characteristics.
RESULTS: Anaplastic lymphoma kinase was positive by immunohistochemistry in 11 (13%) peritoneal mesotheliomas (focal weak in 8, diffuse strong in 3). In focal weak ALK-positive cases, no ALK rearrangement was detected by FISH or next-generation sequencing. In strong diffuse ALK-positive cases, FISH confirmed ALK rearrangements, and next-generation sequencing identified novel fusion partners ATG16L1, STRN, and TPM1. Patients with ALK-rearranged peritoneal mesotheliomas were women and younger than patients without ALK rearrangement (median age 36 vs 62; Mann-Whitney test, P = .02), but all other clinicopathologic characteristics (size of tumor nodules, histology, treatment, and survival) were not different. No asbestos fibers were detected in ALK-rearranged cases. Furthermore, loss of chromosomal region 9p or 22q or genetic alterations in BAP1, SETD2, or NF2 typically present in peritoneal mesothelioma were absent in the ALK-rearranged cases. All pleural mesotheliomas were ALK-negative by immunohistochemistry. CONCLUSIONS AND RELEVANCE: We identified unique ALK rearrangements in a subset of patients with peritoneal mesothelioma, each lacking asbestos fibers, therapeutic radiation, and cytogenetic and molecular alterations typically found in these tumors. Identification of clinically actionable ALK rearrangements may represent a novel pathogenetic mechanism of malignant peritoneal mesothelioma with promise for targeted therapy.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28910456      PMCID: PMC5838580          DOI: 10.1001/jamaoncol.2017.2918

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN: 2374-2437            Impact factor:   31.777


  15 in total

1.  Presence of talc in pelvic lymph nodes of a woman with ovarian cancer and long-term genital exposure to cosmetic talc.

Authors:  Daniel W Cramer; William R Welch; Ross S Berkowitz; John J Godleski
Journal:  Obstet Gynecol       Date:  2007-08       Impact factor: 7.661

2.  Anaplastic lymphoma kinase (ALK) translocation in paediatric malignant peritoneal mesothelioma: a case report of novel ALK-related tumour spectrum.

Authors:  Kongsak Loharamtaweethong; Napaporn Puripat; Nadda Aoonjai; Apisada Sutepvarnon; Chanyoot Bandidwattanawong
Journal:  Histopathology       Date:  2015-09-02       Impact factor: 5.087

3.  Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations.

Authors:  Raphael Bueno; Eric W Stawiski; Leonard D Goldstein; Steffen Durinck; Assunta De Rienzo; Zora Modrusan; Florian Gnad; Thong T Nguyen; Bijay S Jaiswal; Lucian R Chirieac; Daniele Sciaranghella; Nhien Dao; Corinne E Gustafson; Kiara J Munir; Jason A Hackney; Amitabha Chaudhuri; Ravi Gupta; Joseph Guillory; Karen Toy; Connie Ha; Ying-Jiun Chen; Jeremy Stinson; Subhra Chaudhuri; Na Zhang; Thomas D Wu; David J Sugarbaker; Frederic J de Sauvage; William G Richards; Somasekar Seshagiri
Journal:  Nat Genet       Date:  2016-02-29       Impact factor: 38.330

4.  Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer.

Authors:  Lindsey M Kelly; Guillermo Barila; Pengyuan Liu; Viktoria N Evdokimova; Sumita Trivedi; Federica Panebianco; Manoj Gandhi; Sally E Carty; Steven P Hodak; Jianhua Luo; Sanja Dacic; Yan P Yu; Marina N Nikiforova; Robert L Ferris; Daniel L Altschuler; Yuri E Nikiforov
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-03       Impact factor: 11.205

Review 5.  Advances in treatment of lung cancer with targeted therapy.

Authors:  Philip T Cagle; Lucian R Chirieac
Journal:  Arch Pathol Lab Med       Date:  2012-05       Impact factor: 5.534

6.  Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis.

Authors:  Deepa Magge; Mazen S Zenati; Frances Austin; Arun Mavanur; Magesh Sathaiah; Lekshmi Ramalingam; Heather Jones; Amer H Zureikat; Matthew Holtzman; Steven Ahrendt; James Pingpank; Herbert J Zeh; David L Bartlett; Haroon A Choudry
Journal:  Ann Surg Oncol       Date:  2013-12-10       Impact factor: 5.344

Review 7.  ALK as a paradigm of oncogenic promiscuity: different mechanisms of activation and different fusion partners drive tumors of different lineages.

Authors:  Adrian Mariño-Enríquez; Paola Dal Cin
Journal:  Cancer Genet       Date:  2013-10-03

8.  The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma.

Authors:  Aatur D Singhi; Alyssa M Krasinskas; Haroon A Choudry; David L Bartlett; James F Pingpank; Herbert J Zeh; Alyssa Luvison; Kimberly Fuhrer; Nathan Bahary; Raja R Seethala; Sanja Dacic
Journal:  Mod Pathol       Date:  2015-10-23       Impact factor: 7.842

9.  Clinicopathologic characteristics of malignant mesotheliomas arising in patients with a history of radiation for Hodgkin and non-Hodgkin lymphoma.

Authors:  Lucian R Chirieac; Justine A Barletta; Beow Y Yeap; William G Richards; Tamara Tilleman; Raphael Bueno; Elizabeth H Baldini; John Godleski; David J Sugarbaker
Journal:  J Clin Oncol       Date:  2013-11-18       Impact factor: 44.544

10.  The landscape of kinase fusions in cancer.

Authors:  Nicolas Stransky; Ethan Cerami; Stefanie Schalm; Joseph L Kim; Christoph Lengauer
Journal:  Nat Commun       Date:  2014-09-10       Impact factor: 14.919

View more
  37 in total

1.  Personalized treatment of malignant mesothelioma-dream or reality?

Authors:  Anja C Roden
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

2.  Novel insights and recent discoveries on the genetics and pathogenesis of malignant mesothelioma.

Authors:  Yin P Hung; Lucian R Chirieac
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

3.  Molecular characterization of diffuse malignant peritoneal mesothelioma.

Authors:  Yin P Hung; Fei Dong; Matthew Torre; Christopher P Crum; Raphael Bueno; Lucian R Chirieac
Journal:  Mod Pathol       Date:  2020-06-05       Impact factor: 7.842

Review 4.  Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.

Authors:  Michele Carbone; Prasad S Adusumilli; H Richard Alexander; Paul Baas; Fabrizio Bardelli; Angela Bononi; Raphael Bueno; Emanuela Felley-Bosco; Francoise Galateau-Salle; David Jablons; Aaron S Mansfield; Michael Minaai; Marc de Perrot; Patricia Pesavento; Valerie Rusch; David T Severson; Emanuela Taioli; Anne Tsao; Gavitt Woodard; Haining Yang; Marjorie G Zauderer; Harvey I Pass
Journal:  CA Cancer J Clin       Date:  2019-07-08       Impact factor: 508.702

Review 5.  New insights in the pathology of peritoneal surface malignancy.

Authors:  Norman John Carr
Journal:  J Gastrointest Oncol       Date:  2021-04

Review 6.  A Novel Malignant Peritoneal Mesothelioma with STRN Exon 2 and ALK Exon 20: A Case Report and Literature Review.

Authors:  Chiho Miyagawa; Hisamitsu Takaya; Kazuko Sakai; Kazuto Nishio; Maho Konishi; Sachiko Minamiguchi; Toshihide Shimada; Noriomi Matsumura
Journal:  Oncologist       Date:  2021-02-22

Review 7.  Malignant peritoneal mesothelioma: a review.

Authors:  Glenn Broeckx; Patrick Pauwels
Journal:  Transl Lung Cancer Res       Date:  2018-10

8.  Anaplastic Lymphoma Kinase Gene Rearrangement in Children and Young Adults With Mesothelioma.

Authors:  Idrees Mian; Zied Abdullaev; Betsy Morrow; Rosandra N Kaplan; Shaojian Gao; Markku Miettinen; David S Schrump; Valerie Zgonc; Jun S Wei; Javed Khan; Svetlana Pack; Raffit Hassan
Journal:  J Thorac Oncol       Date:  2019-11-26       Impact factor: 15.609

9.  Integrative Molecular Characterization of Malignant Pleural Mesothelioma.

Authors:  Julija Hmeljak; Francisco Sanchez-Vega; Katherine A Hoadley; Juliann Shih; Chip Stewart; David Heiman; Patrick Tarpey; Ludmila Danilova; Esther Drill; Ewan A Gibb; Reanne Bowlby; Rupa Kanchi; Hatice U Osmanbeyoglu; Yoshitaka Sekido; Jumpei Takeshita; Yulia Newton; Kiley Graim; Manaswi Gupta; Carl M Gay; Lixia Diao; David L Gibbs; Vesteinn Thorsson; Lisa Iype; Havish Kantheti; David T Severson; Gloria Ravegnini; Patrice Desmeules; Achim A Jungbluth; William D Travis; Sanja Dacic; Lucian R Chirieac; Françoise Galateau-Sallé; Junya Fujimoto; Aliya N Husain; Henrique C Silveira; Valerie W Rusch; Robert C Rintoul; Harvey Pass; Hedy Kindler; Marjorie G Zauderer; David J Kwiatkowski; Raphael Bueno; Anne S Tsao; Jenette Creaney; Tara Lichtenberg; Kristen Leraas; Jay Bowen; Ina Felau; Jean Claude Zenklusen; Rehan Akbani; Andrew D Cherniack; Lauren A Byers; Michael S Noble; Jonathan A Fletcher; A Gordon Robertson; Ronglai Shen; Hiroyuki Aburatani; Bruce W Robinson; Peter Campbell; Marc Ladanyi
Journal:  Cancer Discov       Date:  2018-10-15       Impact factor: 39.397

10.  Molecular characterization of localized pleural mesothelioma.

Authors:  Yin P Hung; Fei Dong; Adrian M Dubuc; Paola Dal Cin; Raphael Bueno; Lucian R Chirieac
Journal:  Mod Pathol       Date:  2019-08-01       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.